Kumar Siva K, Mather Paul J
Thomas Jefferson University Hospital, Jefferson Medical College, Philadelphia, PA, USA.
Heart Fail Rev. 2009 Jun;14(2):83-6. doi: 10.1007/s10741-008-9107-9. Epub 2008 Sep 3.
In the Adhere (Acute Decompensated Heart Failure Registry) National Registry, hyponatremia (serum sodium <130 mEq/l) at clinical presentation was noted in 5% of patients with HF. The enhanced release of arginine vasopressin (AVP) can lead to hyponatremia by binding to the V2 receptor results in free-water retention and hyponatremia. Given the central role of AVP in causing hyponatremia in patients with congestive heart failure, decreasing vasopressin activity has been a therapeutic focus. With no current therapy to decrease production of AVP, attention was turned to decreasing the effect of AVP by blocking the receptor.
在“坚持（急性失代偿性心力衰竭注册登记）”国家注册登记中，5%的心力衰竭患者在临床表现时存在低钠血症（血清钠<130 mEq/L）。精氨酸加压素（AVP）释放增加，通过与V2受体结合导致自由水潴留和低钠血症。鉴于AVP在充血性心力衰竭患者低钠血症发生中起核心作用，降低加压素活性一直是治疗重点。由于目前尚无降低AVP产生的疗法，于是人们将注意力转向通过阻断受体来降低AVP的作用。
